Max Neeman International was a wholly owned subsidiary of Max India, and one of India’s leading Contract Research Organizations (CROs). Headquartered in New Delhi, the company operated regional offices across Ahmedabad, Bangalore, Chennai, and Mumbai, with a U.S. presence in Raleigh, North Carolina. Max Neeman specialised in clinical trial management, regulatory services, and site monitoring—serving pharmaceutical and biotech clients globally.

JSS Medical Research, headquartered in Montreal, is the largest CRO in Québec and led by Dr. John Sampalis. With a strategic focus on expanding its global footprint, JSS had recently entered Latin America and sought to deepen its presence in Asia through the acquisition of Max Neeman.

Max India appointed Novistra Capital to advise on a strategic sale of its CRO subsidiary. Novistra led the outreach and transaction process, identifying JSS Medical Research as an ideal strategic acquirer looking to enhance its global delivery capabilities and enter the Indian clinical research market.

Novistra managed all commercial and cross-border workstreams, aligning valuation, continuity of management, and integration strategy for the combined entity.

Max Neeman was acquired by JSS Medical Research, enabling JSS to establish a robust clinical operations base in India. The transaction marked a key milestone in JSS’s international expansion and created a unified platform with enhanced capabilities across North America, Latin America, and Asia.

The Max Neeman management team joined the combined entity, ensuring operational continuity and leadership alignment post-transaction.

This deal reflects Novistra’s expertise in healthcare services and life sciences outsourcing, particularly in advising cross-border acquisitions involving corporate carve-outs.